menu
    • menu
    [{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RHB-106","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dibuprenorphine-ethyl-ether","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Fourth Swedish National Pension Fund","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Small molecule","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Linaprazan","moa":"P-CAB","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Cinclus Pharma \/ Fourth Swedish National Pension Fund","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Pharma \/ Fourth Swedish National Pension Fund"},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Vinnova","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"SWEDEN","productType":"Large molecule","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase II","graph3":"InDex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Vinnova","highestDevelopmentStatusID":"8","companyTruncated":"InDex Pharmaceuticals \/ Vinnova"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AG013","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oragenics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Mouth Rinse","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics \/ Not Applicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"BofA Securities","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ BofA Securities"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Thylakoid extract","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Devonian Health Group \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Macrogol","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ColonaryConcepts \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryConcepts \/ Not Applicable"},{"orgOrder":0,"company":"BaseLaunch","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"BaseLaunch","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"BaseLaunch \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BaseLaunch \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BBT-401","moa":"Pellino-1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sibofimloc","moa":"E coli fimH protein blocker","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lovastatin Lactone","moa":"HMG-CoA reductase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Biologics \/ Not Applicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Blautia Hydrogenotrophica","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"IntelGenx \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Tetra Bio-Pharma"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Rifamycin","moa":"DdRP","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill"},{"orgOrder":0,"company":"GSK","sponsor":"Immutep","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"IMP731","moa":"LAG3 Cell","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"GSK \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Immutep"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivarmacitinib","moa":"JAK1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reistone Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"venBio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Financing","leadProduct":"OPL-002","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Spray dried dispersion","sponsorNew":"Ventyx Biosciences \/ venBio","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ venBio"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Celerion","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Celerion"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"InDex Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Cobitolimod","moa":"TLR9","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Parexel Biotech \/ InDex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Biotech \/ InDex Pharmaceuticals"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ National Institutes of Health"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"Seed Health","sponsor":"The Craftory","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"SEED synbiotic","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seed Health","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Seed Health \/ The Craftory","highestDevelopmentStatusID":"8","companyTruncated":"Seed Health \/ The Craftory"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Palisade Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Merger","leadProduct":"Tranexamic Acid","moa":"Serine protease","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Seneca Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Seneca Biopharma"},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"9 Meters Biopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"NM-002","moa":"GLP-1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Duke Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Duke Clinical Research Institute \/ 9 Meters Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Duke Clinical Research Institute \/ 9 Meters Biopharma"},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral drop","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infant Bacterial Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR signalling","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Not Applicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Blautia Hydrogenotrophica","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4Beta7 Integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"LianBio","pharmaFlowCategory":"D","upfrontCash":"$18.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ LianBio","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ LianBio"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Landos Biopharma \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Naronapride","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ Not Applicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Vurolenatide","moa":"GLP-1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Lyophilised Powder For Intravenous","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Public Offering","leadProduct":"VTX002","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Blautia Hydrogenotrophica","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Mucoadesive Tablet","sponsorNew":"Avicanna \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Avicanna \/ Tetra Bio-Pharma"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Oncology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Morning side VENTURE","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Single Strain Live Biotherapeutic Products","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Adiso Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Morning side VENTURE","highestDevelopmentStatusID":"8","companyTruncated":"Adiso Therapeutics \/ Morning side VENTURE"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Qbeco","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Undisclosed"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4beta7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vocacapsaicin","moa":"TRPV1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Concentric Analgesics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Not Applicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PN-943","moa":"Alpha4beta7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Immediate-release Tablet","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer Bio \/ Not Applicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Halobetasol","moa":"Corticosteroid hormone receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pradigastat","moa":"DGAT1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anji Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anji Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Kanyos Bio","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Kanyos Bio","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Kanyos Bio"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Olamkicept","moa":"Il-6","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ferring Pharmaceuticals \/ I-Mab","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ I-Mab"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EpicentRx \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"EsoCap","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-13","moa":"NLRX1","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"Gluten","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunogenX \/ Mayo Clinic","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ Mayo Clinic"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PL8177","moa":"MC1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Peptide","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Mast cell","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vurolenatide","moa":"GLP-1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4beta7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Financing","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer"},{"orgOrder":0,"company":"Zedira","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"TAK-227","moa":"TG2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zedira","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Zedira \/ Takeda","highestDevelopmentStatusID":"8","companyTruncated":"Zedira \/ Takeda"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KAN-101","moa":"IL-2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PL8177","moa":"MC1R","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4beta7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4beta7 integrin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sibofimloc","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enterome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Termination","leadProduct":"2-Fucosyllactose-Synthetic","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Merger","leadProduct":"2-Fucosyllactose-Synthetic","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PF-06480605","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Roivant Sciences \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Pfizer"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LNK01003","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PRA023","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RRx-001","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.5,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Vaccine","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"QBECO-SSI","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Karolinska Institute"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Metacrine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Termination","leadProduct":"MET642","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Equillium","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Equillium \/ Metacrine","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Metacrine"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vurolenatide","moa":"GLP-1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Private Placement","leadProduct":"NX-13","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PF-06480605","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"APPL-001","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celularity \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PL8177","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NX-13","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Not Applicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"RRx-001","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx \/ Not Applicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Not Applicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"RVT-3101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Roivant Sciences \/ Goldman Sachs","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Goldman Sachs"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Pfizer Inc"},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ATI 7505","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Not Applicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BBT-401","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PRA023","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Vurolenatide","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Vurolenatide","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"NImmune Biopharma","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Omilancor","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ NImmune Biopharma"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"LNK01003","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"$10,800.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"PRA023","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":10.800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":10.800000000000001,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Merck & Co. Inc."},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma & Perceptive Advisors","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Deudomperidone","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ CinRx Pharma & Perceptive Advisors","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma & Perceptive Advisors"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"MORF-057","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Deudomperidone","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"MORF-057","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Jefferies"},{"orgOrder":0,"company":"NIMML Institute","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Omilancor","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NIMML Institute","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"NIMML Institute \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"NIMML Institute \/ NImmune Biopharma"},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"MORF-057","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Therapeutic \/ Jefferies"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Omilancor","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NImmune Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NImmune Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NImmune Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"VTX002","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"GSK","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"IMP731","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immutep","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Immutep \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ GSK"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Vurolenatide","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"S1p receptor agonist 1","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"VTX002","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"$10,800.0 million","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Tulisokibart","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":10.800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":10.800000000000001,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus Biosciences \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"PF-06480605","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Pfizer Inc"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Not Applicable"},{"orgOrder":0,"company":"EsoCap","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ Not Applicable"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"KU Leuven","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"NX-13","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ KU Leuven","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ KU Leuven"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"$500.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"TEV-48574","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":1.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":1.5,"dosageForm":"Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Sanofi"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Vedanta Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Vedanta Biosciences"},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"AGMB-129","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb Therapeutics N.V \/ Not Applicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VTX002","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","upfrontCash":"$7,100.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"PF-06480605","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Telavant","amount2":7.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":7.25,"dosageForm":"Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","upfrontCash":"$50.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"JNJ-2113","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.98999999999999999,"dosageForm":"Tablet","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","upfrontCash":"$7,100.0 million","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"RVT-3101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Telavant","amount2":7.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":7.25,"dosageForm":"Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"IRL201104","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CinPhloro Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Phloroglucinol","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinPhloro Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinPhloro Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinPhloro Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"March 2024","year":"2024","type":"Merger","leadProduct":"Latiglutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","upfrontCash":"$137.5 million","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"NX-13","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Landos Biopharma \/ Abbvie Inc"},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma GmbH","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Naronapride","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion \/ Dr. Falk Pharma GmbH"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"VTX002","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Immuron","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"March 2024","year":"2024","type":"Funding","leadProduct":"Bovine Colostrum","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Immuron \/ U.S. Department of Defense"},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Merger","leadProduct":"Latiglutenase","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX \/ First Wave BioPharma"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ Not Applicable"},{"orgOrder":0,"company":"EsoCap","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Amiselimod HCl","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EBX-102-02","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Not Applicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Financing","leadProduct":"EBX-102-02","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiotix \/ Thairm Bio"},{"orgOrder":0,"company":"MRM Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"MH002","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"MRM Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MRM Health \/ Not Applicable"},{"orgOrder":0,"company":"AltruBio","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"Leiolizumab","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"AltruBio \/ BVF Partners LP","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/ BVF Partners LP"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Gastroenterology","country":"","productType":"Peptide","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"KAN-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"Deudomperidone","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"CinRx Pharma \/ CinRx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Pharma \/ CinRx Pharma"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"Metopimazine Mesylate","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Vivo Capital"}]

    Find Gastroenterology Drugs in Phase II Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Innovent Biologics

                            China arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Innovent Biologics

                            China arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Picankibart

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innovent’s Phase 2 Study of Picankibart in Ulcerative Colitis Meets Primary Endpoint

                            Details : IBI112 (picankibart) is a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection. It is being evaluated in chinese subjects with moderately to severely active ulcerative colitis.

                            Brand Name : IBI112

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 16, 2024

                            Lead Product(s) : Picankibart

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Innovent Biologics

                            China arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Innovent Biologics

                            China arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Picankibart

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Innovent’s Phase 2 Study of Picankibart in Ulcerative Colitis Meets Primary Endpoint

                            Details : IBI112 (picankibart) an antibody, specifically binds to IL-23p19 inhibiting IL-23 receptor-mediated signaling pathway. It is being investigated in patients with moderate to severe ulcerative colitis.

                            Brand Name : IBI112

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 16, 2024

                            Lead Product(s) : Picankibart

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Abivax

                            France arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Abivax

                            France arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obefazimod

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Abivax Announces First Patient Enrolled in ENHANCE-CD Trial of Obefazimod in Crohn’s

                            Details : ABX464 (obefazimod) is an oral small molecule that was demonstrated to potentially enhance the expression of miR-124, being evaluated for moderate to severe crohn’s disease.

                            Brand Name : ABX464

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 03, 2024

                            Lead Product(s) : Obefazimod

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Morphic Therapeutic

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Morphic Therapeutic

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MORF-057

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Eli Lilly

                            Deal Size : $3,200.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly Completes Acquisition of Morphic to Improve Outcomes for Inflammatory Bowel Disease

                            Details : The acquisition expands Lilly's immunology pipeline with MORF-057, a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD).

                            Brand Name : MORF-057

                            Molecule Type : Small molecule

                            Upfront Cash : $3,200.0 million

                            August 16, 2024

                            Lead Product(s) : MORF-057

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Eli Lilly

                            Deal Size : $3,200.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Renexxion

                            Ireland arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Renexxion

                            Ireland arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naronapride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Dr. Falk Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renexxion and Dr. Falk Expand Phase 2b Study of Naronapride in Gastroparesis

                            Details : ATI 7505 (naronapride) is a potential best-in-class oral, locally acting pan-GI prokinetic, that acts as 5-HT4R agonist and D2R antagonist. It is being evaluated for the treatment of Gastroparesis.

                            Brand Name : ATI 7505

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 13, 2024

                            Lead Product(s) : Naronapride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Dr. Falk Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ventyx Biosciences

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Ventyx Biosciences

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VTX958

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ventyx Biosciences Announces Results from Phase 2 Trial of VTX958 in Crohn’s Disease

                            Details : VTX002 is a potent and selective, orally bioavailable small molecule modulator of the S1P1 receptor and being investigated for Patients with moderately to severely active crohn’s disease.

                            Brand Name : VTX958

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 29, 2024

                            Lead Product(s) : VTX958

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Revolo Biotherapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Revolo Biotherapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IRL201104

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Revolo Data Validates Subcutaneous Administration of ‘1104 for Immune Disorders

                            Details : ‘1104 (IRL201104) is a first-in-class immune-resetting peptide, which is being evaluated in phase 2 clinical trials for the treatment of eosinophilic esophagitis (EoE).

                            Brand Name : ‘1104

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 24, 2024

                            Lead Product(s) : IRL201104

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            OSE Immunotherapeutics SA

                            France arrow
                            Aquaexpo 2024
                            Not Confirmed

                            OSE Immunotherapeutics SA

                            France arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lusvertikimab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OSE Immunotherapeutics Announces Positive Results for Lusvertikimab in Colitis

                            Details : OSE-127 (lusvertikimab) is a humanized monoclonal antibody targeting the IL-7 receptor, currently in Phase 2 trials for ulcerative colitis. It shows promising efficacy and a favorable safety profile.

                            Brand Name : OSE-127

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 24, 2024

                            Lead Product(s) : Lusvertikimab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Teva Pharmaceutical Industries

                            Israel arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Teva Pharmaceutical Industries

                            Israel arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A in Bowel Disease

                            Details : TEV-’574 (duvakitug) is a potential best-in-class human IgG1-lambda 2 mAb that targets tumor necrosis factor (TNF)-like ligand 1A, also known as TNF superfamily member 15 (TNFSF15).

                            Brand Name : TEV-48574

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 24, 2024

                            Lead Product(s) : Duvakitug

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Morphic Therapeutic

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Morphic Therapeutic

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MORF-057

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Eli Lilly

                            Deal Size : $3,200.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

                            Details : The acquisition expands Lilly's immunology pipeline with MORF-057, a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD).

                            Brand Name : MORF-057

                            Molecule Type : Small molecule

                            Upfront Cash : $3,200.0 million

                            July 08, 2024

                            Lead Product(s) : MORF-057

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Eli Lilly

                            Deal Size : $3,200.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth